Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer

NCT03432598 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Lung Cancer; Metastatic Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Paclitaxel
DRUG: Gemcitabine
DRUG: Etoposide
DRUG: Pemetrexed
DRUG: Cisplatin
DRUG: Carboplatin

Sponsor

BeiGene